Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer

ABSTRACT

Introduction

The resistance to chemotherapy is a significant hurdle in breast cancer treatment, prompting the exploration of innovative strategies. This review discusses the potential of dual-loaded liposomal carriers to combat chemoresistance and improve outcomes for breast cancer patients.

Areas covered

This review discusses breast cancer chemotherapy resistance and dual-loaded liposomal carriers. Drug efflux pumps, DNA repair pathways, and signaling alterations are discussed as chemoresistance mechanisms. Liposomes can encapsulate several medicines and cargo kinds, according to the review. It examines how these carriers improve medication delivery, cancer cell targeting, and tumor microenvironment regulation. Also examined are dual-loaded liposomal carrier improvement challenges and techniques.

Expert opinion

The use of dual-loaded liposomal carriers represents a promising and innovative strategy in the battle against chemotherapy resistance in breast cancer. This article has explored the various mechanisms of chemoresistance in breast cancer, emphasizing the potential of dual-loaded liposomal carriers to overcome these challenges. These carriers offer versatility, enabling the encapsulation and precise targeting of multiple drugs with different modes of action, a crucial advantage when dealing with the complexity of breast cancer treatment.

KEYWORDS:

• Chemotherapy
• resistance
• liposomes
• nanocarriers
• immunomodulators

Article highlights

• The paper discusses the challenge of chemotherapy resistance in breast cancer and explores dual-loaded liposomal carriers as a potential solution.

• It highlights the mechanisms of chemoresistance in breast cancer, including drug efflux pumps, DNA repair pathways, and signaling alterations.

• The versatility of liposomes in encapsulating multiple drugs and cargo types is emphasized, along with their ability to improve drug delivery, cancer cell targeting, and tumor microenvironment regulation.

• The paper examines the challenges in improving dual-loaded liposomal carriers, like stability and precision, and explores innovative approaches for enhancement.

• Clinical and preclinical evidence supporting the efficacy of dual-loaded liposomal carriers in breast cancer treatment is analyzed, highlighting their role in overcoming chemotherapy resistance.

• The paper concludes with the promising potential of dual-loaded liposomal carriers in personalized and effective breast cancer treatment strategies, while acknowledging the need for further research and development.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.